Effectiveness of the information technology-aided program of relapse prevention in schizophrenia (ITAREPS): a randomized, controlled, double-blind study
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
PubMed
22805901
DOI
10.1097/01.pra.0000416017.45591.c1
PII: 00131746-201207000-00005
Knihovny.cz E-zdroje
- MeSH
- adherence pacienta MeSH
- analýza podle původního léčebného záměru MeSH
- analýza přežití MeSH
- časná diagnóza MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- průzkumy a dotazníky * MeSH
- psychotické poruchy diagnóza rehabilitace MeSH
- schizofrenie diagnóza rehabilitace MeSH
- sekundární prevence MeSH
- telemedicína metody MeSH
- znovupřijetí pacienta statistika a číselné údaje MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
PURPOSE: To evaluate the effectiveness of the Information Technology-Aided Program of Re lapse Prevention in Schizophrenia (ITAREPS). METHODS: Relapse-prone outpatients with schizophrenia or schizoaffective disorder were randomized to the active (n=75) or control group (n=71). In the active arm, according to the protocol, investigators were prompted to increase the antipsychotic dose upon occurrence of a pharmacological inter vention requiring event (PIRE) detected by ITAREPS. RESULTS: Intention-to-treat (ITT) analysis found no between-group difference in the hospitalization-free survival rate at 12 months. However, the trial suffered from high non-adherence of investigators in the active group, with no antipsychotic dose increase in 61% of PIREs. Furthermore, Cox regression analysis showed a 11-fold increased risk of hospitalization in the absence of pharmacological intervention following a PIRE (hazard ratio [HR]=10.8; 95% confidence interval [CI] 1.4-80.0; p=0.002). Therefore, a post-hoc as-treated analysis was performed, which demonstrated a nine-fold reduction in the risk of hospitalization in ITAREPS Algorithm-Adherers (IAAs, n=25) compared with the ITAREPS Non-interventional group (INIs, n=70; Kaplan-Meier survival analysis, HR=0.11, 95% CI 0.05-0.28, p=0.009; number needed to treat [NNT]=4, 95% CI 3-10). A significant difference in favor of the IAA group was seen in the number of inpatient days (p<0.05) and costs (p<0.05). CONCLUSION: Future ITAREPS trials should target the underlying mechanisms that cause low investigator adherence to the program. TRIAL REGISTRATION: Clinical Trials NCT00712660.
Citace poskytuje Crossref.org
ClinicalTrials.gov
NCT00712660